Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo

J Am Acad Dermatol. 2023 Dec;89(6):1257-1259. doi: 10.1016/j.jaad.2023.07.1016. Epub 2023 Jul 28.

Authors

Xinhong Su¹, Renwei Luo¹, Shifan Ruan¹, Qingmei Zhong¹, Zheyu Zhuang¹, Zhixun Xiao¹, Peng Zhang¹, Bo Cheng¹, Ting Gong², Chao Ji³

Affiliations

¹ Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
² Central Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China. Electronic address: derma123@126.com.
³ Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China. Electronic address: jichaofy@fjmu.edu.cn.

PMID: 37516357
DOI: 10.1016/j.jaad.2023.07.1016

No abstract available

Keywords: JAK1 inhibitor; efficacy; recalcitrant vitiligo; safety; upadacitinib.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents* / adverse effects
Double-Blind Method
Heterocyclic Compounds, 3-Ring / adverse effects
Humans
Methotrexate / adverse effects
Treatment Outcome
Vitiligo* / chemically induced
Vitiligo* / drug therapy

Substances

upadacitinib
Antirheumatic Agents
Methotrexate
Heterocyclic Compounds, 3-Ring